Please provide your email address to receive an email when new articles are posted on . Research linking fluctuations in bone marrow lesions with pain fluctuations may suggest that targeting these ...

Please provide your email address to receive an email when new articles are posted on . NASHVILLE, Tenn. — Subchondral bone lesions can usually be managed nonoperatively. However, once collapse occurs ...

The aim of this retrospective investigation was to compare the diagnostic performance of a fully integrated whole-body PET/MRI scanner (Biograph mMR; Siemens Medical Solutions; Malvern, Pennsylvania) ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its ...

A study of samples from patients with multiple myeloma (MM) has demonstrated how "reprogrammed" fat cells contribute to long-lasting bone damage, even after the cancer has gone into remission.

Dervis, A. (2025) Curative Outcome of Osteosarcoma with Associated Pleural Effusion: A Case Report —Bone Tumor with Pleural ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in collaboration with leading German universities, has developed a new biomaterial ...

Eosinophilic granuloma (EG) is a type of lesion that usually appears on bones. These lesions are caused by an overgrowth of Langerhans cells, which are naturally occurring white blood cells that are ...

Patients with midfoot pain and MRI-detected bone marrow lesions who wore firm foot orthoses achieved greater reductions in pain and bone marrow lesion volume over 12 weeks than those who wore ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients. These ...